Martin Münchbach

After graduating from the ETH Zurich in natural sciences with a doctorate in protein chemistry and a post-graduate degree in economics, business and management sciences from the ETH Zurich, he worked in various positions for venture capital companies in Switzerland.

Since 2004, he has been Senior Investment Advisor Private Equity at Bellevue Asset Management AG in Küsnacht, ZH and is currently Managing Partner of BB Pureos Bioventures, a venture capital company specializing in early-stage financing for the promotion of innovative young drug development companies with a focus on Switzerland and Europe. Through his work as a venture capitalist, he has built up numerous medical technology and biotechnology companies that have brought innovative drugs and diagnostics to market. Martin Münchbach has served on the

Board of Directors of 4-Antibody AG in Basel, Optimer Pharmaceuticals Inc. in San Diego, USA and Radius Health Inc. in Waltham, USA, among others. He is currently a Director of Alentis Therapeutics AG in Basel and Binx Health Ltd. in Trowbridge, UK.